Medical Companies

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Anadis Limited (ASX Symbol: ANX) is an Australian biotech company that delivers on the promise of biotech. It does this by bringing to market healthcare products based on the achievements of the medical research community in Melbourne, Australia. An exception to the rule, Anadis demonstrates that biotech can do commercialization. With expertise in research, commercialization and manufacturing Anadis specializes in innovative, pharmaceutical, nutraceutical and related therapeutic technology products, primarily for use in and by, humans. With patented technologies Anadis develops new pharmaceutical products based, in part, on natural substances to benefit health. The efficacy of scientific developments is proven by rigorous independent medical clinical ( www.anadis.com.au )

Anadis Ltd
4 Capital Link Drive
Campbellfield, Victoria 3061
Australia

Tel: +61 3 9358 6388
Fax: +61 3 9358 6399

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Prana Biotechnology was established to commercialise research into Alzheimer’s disease and other major age-related neurodegenerative disorders. The company was incorporated in 1997 and listed on the Australian Stock Exchange in March 2000 and listed on NASDAQ in September 2002. Researchers at prominent international institutions including the University of Melbourne, The Mental Health Research Institute (Melbourne) and Massachusetts General Hospital, a teaching hospital of Harvard Medical School, discovered Prana’s technology. ( www.pranabio.com )

Prana Biotechnology Limited
Principal Office Level 2 369 Royal Parade
Parkville, Victoria 3052
Australia

Tel: +61 3 9349 4906
Fax: +61 3 9348 0377

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Neuren Pharmaceuticals (ASX: NEU) is a biopharmaceutical company developing novel therapeutics in the fields of neural repair and rescue and metabolic disorders. The Neuren portfolio consists of six product families, targeting markets with large unmet needs and limited competition. Neuren has two lead clinical candidates, Glypromate® and NNZ-2566, presently in development to treat a range of acute neurological conditions. Neuren has commercial and development partnerships, including with Pfizer, the US Army’s Walter Reed Army Institute of Research and Metabolic Pharmaceuticals. ( www.neurenpharma.com )

Neuren Pharmaceuticals Limited
Level 13 122 Arthur St
North Sydney, New South Wales 2060
Australia

Tel: +64 9 529 3940
Fax: +64 9 529 3941

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Biota is a world-leading antiviral drug discovery company with its headquarters in Melbourne, Australia. Biota’s first breakthrough was the discovery of zanamivir, the first neuraminidase inhibitor, subsequently marketed by GlaxoSmithKline as Relenza for the treatment of influenza. In partnership with Thermo Electron, Biota markets the FLU OIA® diagnostics range for the rapid detection of influenza. In partnership with Sankyo, Biota is engaged in the development of second generation flu antivirals (LANI or Long Acting Neuraminidase Inhibitors). Biota also has active discovery and development programs aimed at new therapies for diseases caused by Human Rhinovirus (common cold), RSV (Respiratory Syncytial Virus), HIV, and hepatitis C. ( www.biota.com.au )

Biota Holdings Limited
Unit 10 585 Blackburn Road
Notting Hill, Victoria 3168
AUSTRALIA

Tel: +61 3 9915 3700

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
About Progen: Progen Industries Limited is an Australian based globally focused biotechnology company committed to the discovery, development and commercialisation of small molecule pharmaceuticals for the treatment of cancer and other serious diseases. ( www.progen.com.au )

Progen Industries Limited
16 Benson St
Toowong, Queensland 4066
Australia

Tel: +61 7 3842 3333
Fax: +61 7 3720 9624

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Actelion Ltd is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion’s first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. At the end of September 2006, Tracleer® was commercially available in 35 countries worldwide. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium – the single layer of cells separating every blood vessel from the blood ( www.actelion.com )

Actelion Ltd
PO Box 372
Frenchs Forest, New South Wales 1640
Australia

Tel: +61 2 9486 4600
Fax: +61 2 9986 1344

Industry: Pharmaceuticals, Biotechnology
Replikun Biotech Pty Limited is a private, venture capital backed company established in 2005. Replikun Biotech’s origins date back to 1960, when Professor Edwin Westaway isolated the Kunjin virus from Cx. annulirostris mosquitoes in northern Queensland. The virus was given the name of a nearby Aboriginal clan living on the Mitchell River. The discovery of Kunjin was exciting because it provided a safe means of studying flavivirus replication in the laboratory. In 1995, Professor Westaway and Associate Professor Alex Khromykh showed that the structural protein genes could be removed from the Kunjin genome without disturbing ( www.replikun.com )

Replikun Biotech Pty Limited
Level 1 80 Jephson Street
Toowong, Queensland 4066
AUSTRALIA

Tel: +61 7 3327 9829
Fax: +61 7 3720 9574

Industry: Pharmaceuticals, Biotechnology
Spinifex focuses on pain because it is an area of high unmet medical need, and therefore provides many commercial opportunities. Demand for pain drugs continues to increase, fuelling the growth of a market that is expected to be worth US,75 billion annually by 2010. With most types of pain still poorly treated, considerable investment is being made internationally in discovering novel approaches to treat pain, providing Spinifex with a wide choice of early-stage drugs from which to license products for development. ( www.spinifexpharma.com.au )

Spinifex Pharmaceuticals Pty Limited
Level 2, 147 Coronation Drive
Milton, Queensland 4064
AUSTRALIA

Tel: +61 7 3025 3216
Fax: +61 7 3025 3300

Industry: Pharmaceuticals, Biotechnology
MitoSciences was founded in the summer of 2003 by Drs Roderick Capaldi and Michael Marusich with the mission of advancing mitochondrial research, and in particular, efforts to understand the role of the organelle in human diseases. The Company has produced and continues to add to the world’s largest collection of anti-mitochondrial monoclonal antibodies. These antibodies are being sold for life sciences research, developed into kits for drug discovery and drug toxicity studies, as well as being developed into tools for the diagnosis of the many mitochondrial-related diseases and for diagnosing mitochondrial toxicity from HAART. The Company is located in the Riverfront Research Park of the University of Oregon. ( www.mitosciences.com )

MitoSciences Inc
Suite 1 134 Redfern Street
Redfern, New South Wales 2016
Australia

Tel: +61 2 9698 2022
Fax: +61 2 9698 1022

Industry: Pharmaceuticals, Biotechnology
ACYTE Biotech was incorporated in June 2000 to commercialise intellectual property arising from a mammalian cell research group at the University of New South Wales. The two co-founders of the company are Professor Peter Gray and A/Professor Noelle-Anne Sunstrom. Major R&D activities for the company commenced in 2002. Since then, ACYTE’s operations have been funded by contracts with major international pharma and biotech companies and three Biotechnology Innovation Fund grants (BIF grants) from the Australian Federal Government. ACYTE staff has expertise ranging from molecular biology through to cell culture and protein ( www.acyte.com )

Acyte Biotech Pty Ltd
Rupert Myers Building Barker Street
Sydney, New South Wales 2052
Australia

Tel: +61 2 9385 3693